Concepts (237)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 24 | 2020 | 420 | 3.200 |
Why?
|
| Daptomycin | 9 | 2013 | 13 | 1.680 |
Why?
|
| Staphylococcal Infections | 6 | 2018 | 185 | 1.290 |
Why?
|
| Prosthesis-Related Infections | 7 | 2020 | 222 | 1.150 |
Why?
|
| Cross Infection | 5 | 2023 | 309 | 1.040 |
Why?
|
| Anti-Infective Agents | 10 | 2005 | 63 | 0.940 |
Why?
|
| Gram-Positive Bacterial Infections | 5 | 2013 | 58 | 0.910 |
Why?
|
| Clostridium Infections | 1 | 2023 | 23 | 0.880 |
Why?
|
| Communicable Diseases | 1 | 2023 | 24 | 0.880 |
Why?
|
| Bacterial Infections | 5 | 2011 | 72 | 0.870 |
Why?
|
| Staphylococcus aureus | 7 | 2018 | 88 | 0.790 |
Why?
|
| Infection Control | 3 | 2018 | 177 | 0.750 |
Why?
|
| Catheterization, Central Venous | 2 | 2011 | 43 | 0.660 |
Why?
|
| Fluoroquinolones | 7 | 2011 | 28 | 0.630 |
Why?
|
| Skin Diseases, Bacterial | 3 | 2018 | 5 | 0.630 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 103 | 0.620 |
Why?
|
| Sepsis | 3 | 2011 | 154 | 0.620 |
Why?
|
| Bacteria | 4 | 2011 | 89 | 0.600 |
Why?
|
| Soft Tissue Infections | 3 | 2018 | 29 | 0.600 |
Why?
|
| Bacteremia | 2 | 2010 | 119 | 0.580 |
Why?
|
| Enterococcus | 4 | 2013 | 57 | 0.560 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2016 | 132 | 0.530 |
Why?
|
| Humans | 50 | 2023 | 30997 | 0.510 |
Why?
|
| Arthroplasty, Replacement | 1 | 2017 | 150 | 0.500 |
Why?
|
| Endocarditis, Bacterial | 2 | 2006 | 9 | 0.440 |
Why?
|
| Oxazolidinones | 2 | 2010 | 6 | 0.430 |
Why?
|
| Microbial Sensitivity Tests | 12 | 2018 | 115 | 0.430 |
Why?
|
| Acetamides | 2 | 2010 | 7 | 0.430 |
Why?
|
| Vancomycin Resistance | 2 | 2010 | 29 | 0.420 |
Why?
|
| Quinolones | 5 | 1991 | 21 | 0.370 |
Why?
|
| Methicillin Resistance | 2 | 2008 | 31 | 0.370 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2016 | 39 | 0.330 |
Why?
|
| Retrospective Studies | 11 | 2023 | 3658 | 0.320 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 27 | 0.310 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2019 | 17 | 0.310 |
Why?
|
| Hospitals, University | 1 | 2008 | 41 | 0.310 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 155 | 0.300 |
Why?
|
| Benchmarking | 1 | 2008 | 46 | 0.300 |
Why?
|
| Pneumonia, Bacterial | 2 | 2005 | 12 | 0.290 |
Why?
|
| Quality of Health Care | 2 | 2011 | 146 | 0.290 |
Why?
|
| Cefazolin | 2 | 2018 | 5 | 0.290 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 191 | 0.280 |
Why?
|
| Chlamydia trachomatis | 4 | 1991 | 18 | 0.280 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2007 | 24 | 0.280 |
Why?
|
| United States | 6 | 2017 | 2375 | 0.260 |
Why?
|
| Bone Diseases | 1 | 2005 | 24 | 0.260 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2020 | 688 | 0.260 |
Why?
|
| Microbiological Techniques | 2 | 2016 | 9 | 0.250 |
Why?
|
| Critical Care | 1 | 2008 | 246 | 0.250 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2020 | 860 | 0.250 |
Why?
|
| Ambulatory Care | 1 | 2005 | 79 | 0.240 |
Why?
|
| Joint Diseases | 1 | 2005 | 114 | 0.240 |
Why?
|
| Infection Control Practitioners | 1 | 2004 | 2 | 0.230 |
Why?
|
| Equipment Contamination | 1 | 2004 | 24 | 0.230 |
Why?
|
| Ambulatory Care Facilities | 1 | 2004 | 39 | 0.230 |
Why?
|
| Knee Prosthesis | 2 | 2020 | 240 | 0.220 |
Why?
|
| Hospitals | 1 | 2023 | 165 | 0.200 |
Why?
|
| Treatment Outcome | 10 | 2015 | 3806 | 0.200 |
Why?
|
| Hip Prosthesis | 3 | 2020 | 578 | 0.190 |
Why?
|
| Disease Management | 2 | 2019 | 126 | 0.180 |
Why?
|
| Cephalosporins | 3 | 1997 | 17 | 0.180 |
Why?
|
| Adult | 13 | 2018 | 8931 | 0.180 |
Why?
|
| Orthopedic Fixation Devices | 1 | 1999 | 25 | 0.170 |
Why?
|
| Heart Valve Prosthesis | 1 | 1999 | 21 | 0.170 |
Why?
|
| Male | 17 | 2020 | 16445 | 0.170 |
Why?
|
| Discitis | 1 | 2019 | 4 | 0.170 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 28 | 0.170 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2011 | 54 | 0.160 |
Why?
|
| Genes, Bacterial | 1 | 2018 | 6 | 0.160 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 13 | 0.160 |
Why?
|
| Linezolid | 2 | 2010 | 6 | 0.150 |
Why?
|
| Middle Aged | 12 | 2020 | 10195 | 0.150 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2018 | 40 | 0.150 |
Why?
|
| Carrier State | 1 | 2018 | 52 | 0.150 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2018 | 7 | 0.150 |
Why?
|
| Reoperation | 2 | 2020 | 950 | 0.140 |
Why?
|
| Meningitis, Bacterial | 1 | 1996 | 8 | 0.140 |
Why?
|
| Aged | 10 | 2020 | 10048 | 0.140 |
Why?
|
| Mass Screening | 1 | 2018 | 186 | 0.140 |
Why?
|
| Legionella pneumophila | 1 | 1996 | 1 | 0.140 |
Why?
|
| Clarithromycin | 1 | 1996 | 5 | 0.140 |
Why?
|
| Erythromycin | 1 | 1996 | 10 | 0.140 |
Why?
|
| Azithromycin | 1 | 1996 | 4 | 0.140 |
Why?
|
| Prosthesis Failure | 1 | 2020 | 539 | 0.130 |
Why?
|
| Female | 13 | 2020 | 16983 | 0.130 |
Why?
|
| Oxacillin | 1 | 2015 | 2 | 0.130 |
Why?
|
| Arthroplasty | 1 | 2016 | 141 | 0.130 |
Why?
|
| Methicillin | 1 | 2015 | 8 | 0.130 |
Why?
|
| Drug Hypersensitivity | 1 | 1995 | 14 | 0.130 |
Why?
|
| Chicago | 4 | 2018 | 943 | 0.130 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 2 | 1991 | 3 | 0.130 |
Why?
|
| Diarrhea | 3 | 1990 | 48 | 0.120 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 5189 | 0.120 |
Why?
|
| Ceftizoxime | 1 | 1994 | 2 | 0.120 |
Why?
|
| Neisseria gonorrhoeae | 2 | 1991 | 8 | 0.110 |
Why?
|
| Cyclic N-Oxides | 1 | 1993 | 5 | 0.110 |
Why?
|
| Campylobacter | 1 | 1993 | 8 | 0.110 |
Why?
|
| Endocarditis | 1 | 2013 | 10 | 0.110 |
Why?
|
| Quinoxalines | 1 | 1993 | 11 | 0.110 |
Why?
|
| Enterococcus faecalis | 1 | 2013 | 7 | 0.110 |
Why?
|
| Enterococcus faecium | 1 | 2013 | 15 | 0.110 |
Why?
|
| Drainage | 1 | 2013 | 52 | 0.110 |
Why?
|
| Uterine Cervicitis | 1 | 1991 | 2 | 0.100 |
Why?
|
| Urethritis | 1 | 1991 | 2 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2015 | 2043 | 0.100 |
Why?
|
| Aza Compounds | 1 | 2011 | 1 | 0.100 |
Why?
|
| Administration, Ophthalmic | 1 | 2011 | 1 | 0.100 |
Why?
|
| Azepines | 1 | 2011 | 6 | 0.100 |
Why?
|
| Quinolines | 1 | 2011 | 16 | 0.100 |
Why?
|
| 4-Quinolones | 4 | 1995 | 6 | 0.100 |
Why?
|
| Serratia marcescens | 1 | 2010 | 11 | 0.090 |
Why?
|
| Serratia Infections | 1 | 2010 | 10 | 0.090 |
Why?
|
| Naphthyridines | 1 | 1990 | 6 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 57 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2011 | 71 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 148 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 100 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 93 | 0.090 |
Why?
|
| Illinois | 1 | 2011 | 267 | 0.090 |
Why?
|
| Models, Biological | 1 | 2011 | 346 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 341 | 0.080 |
Why?
|
| Tetracyclines | 1 | 1989 | 3 | 0.080 |
Why?
|
| Rifampin | 1 | 1989 | 6 | 0.080 |
Why?
|
| Drug Resistance, Microbial | 3 | 1996 | 96 | 0.080 |
Why?
|
| Minocycline | 1 | 1989 | 8 | 0.080 |
Why?
|
| Shock, Septic | 1 | 1989 | 67 | 0.080 |
Why?
|
| Time Factors | 4 | 2020 | 1672 | 0.080 |
Why?
|
| Neurocognitive Disorders | 1 | 1988 | 19 | 0.080 |
Why?
|
| Algorithms | 1 | 2010 | 414 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 93 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2008 | 68 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2007 | 17 | 0.070 |
Why?
|
| Vancomycin | 1 | 2008 | 59 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2008 | 42 | 0.070 |
Why?
|
| Skin Diseases, Infectious | 1 | 2007 | 9 | 0.070 |
Why?
|
| Prognosis | 1 | 2010 | 919 | 0.070 |
Why?
|
| Q Fever | 1 | 2006 | 4 | 0.070 |
Why?
|
| Travel | 1 | 2006 | 14 | 0.070 |
Why?
|
| Community-Acquired Infections | 2 | 2005 | 82 | 0.070 |
Why?
|
| Registries | 1 | 2007 | 203 | 0.070 |
Why?
|
| Tobramycin | 1 | 2005 | 10 | 0.060 |
Why?
|
| Calcium Sulfate | 1 | 2005 | 20 | 0.060 |
Why?
|
| Bone Substitutes | 1 | 2005 | 27 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2011 | 442 | 0.060 |
Why?
|
| Humerus | 1 | 2005 | 103 | 0.060 |
Why?
|
| Animals | 2 | 2011 | 4723 | 0.060 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2004 | 5 | 0.060 |
Why?
|
| Doxycycline | 3 | 2006 | 20 | 0.060 |
Why?
|
| Risk Factors | 1 | 2011 | 2588 | 0.060 |
Why?
|
| Bone Transplantation | 1 | 2005 | 234 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 344 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2020 | 139 | 0.050 |
Why?
|
| Ciprofloxacin | 3 | 1993 | 28 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 2 | 2007 | 37 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 407 | 0.050 |
Why?
|
| Ofloxacin | 2 | 1997 | 5 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2005 | 1922 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2018 | 15 | 0.040 |
Why?
|
| Gas Gangrene | 1 | 2018 | 1 | 0.040 |
Why?
|
| Leukocidins | 1 | 2018 | 2 | 0.040 |
Why?
|
| Rectum | 1 | 2018 | 66 | 0.040 |
Why?
|
| Dermatomycoses | 1 | 2018 | 3 | 0.040 |
Why?
|
| Exotoxins | 1 | 2018 | 14 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2018 | 10 | 0.040 |
Why?
|
| Pyomyositis | 1 | 2018 | 5 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 28 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 74 | 0.040 |
Why?
|
| Bacterial Toxins | 1 | 2018 | 21 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2018 | 31 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 532 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 50 | 0.040 |
Why?
|
| Prodrugs | 1 | 1997 | 3 | 0.040 |
Why?
|
| Ceftriaxone | 1 | 1997 | 5 | 0.040 |
Why?
|
| Cefuroxime | 1 | 1997 | 2 | 0.040 |
Why?
|
| Levofloxacin | 1 | 1997 | 6 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 156 | 0.040 |
Why?
|
| Prevalence | 1 | 2018 | 500 | 0.030 |
Why?
|
| Legionnaires' Disease | 1 | 1996 | 1 | 0.030 |
Why?
|
| Emergencies | 1 | 1996 | 40 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 1996 | 21 | 0.030 |
Why?
|
| Campylobacter Infections | 2 | 1993 | 11 | 0.030 |
Why?
|
| Acute Disease | 1 | 1996 | 231 | 0.030 |
Why?
|
| Skin Tests | 1 | 1995 | 13 | 0.030 |
Why?
|
| Listeriosis | 1 | 1995 | 6 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2018 | 328 | 0.030 |
Why?
|
| Adolescent | 2 | 2018 | 2401 | 0.030 |
Why?
|
| Staphylococcus | 1 | 1995 | 10 | 0.030 |
Why?
|
| Drug Utilization | 1 | 1995 | 30 | 0.030 |
Why?
|
| Arthritis, Infectious | 1 | 1995 | 63 | 0.030 |
Why?
|
| Campylobacter coli | 1 | 1993 | 2 | 0.030 |
Why?
|
| Metronidazole | 1 | 1993 | 9 | 0.030 |
Why?
|
| Borrelia burgdorferi Group | 1 | 1993 | 6 | 0.030 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1993 | 16 | 0.030 |
Why?
|
| Contraindications | 1 | 2013 | 42 | 0.030 |
Why?
|
| Blood | 1 | 2013 | 25 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2013 | 33 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 225 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 320 | 0.030 |
Why?
|
| Osteoarthritis, Hip | 1 | 2013 | 95 | 0.030 |
Why?
|
| Ureaplasma urealyticum | 1 | 1991 | 1 | 0.030 |
Why?
|
| Mycoplasma | 1 | 1991 | 4 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2013 | 1897 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 2063 | 0.020 |
Why?
|
| Treponema pallidum | 1 | 1991 | 7 | 0.020 |
Why?
|
| Gonorrhea | 1 | 1991 | 9 | 0.020 |
Why?
|
| Serratia | 1 | 2010 | 7 | 0.020 |
Why?
|
| Syringes | 1 | 2010 | 11 | 0.020 |
Why?
|
| Blood Sedimentation | 1 | 2010 | 65 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 61 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 132 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1990 | 7 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 128 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 90 | 0.020 |
Why?
|
| Norfloxacin | 1 | 1989 | 2 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1989 | 66 | 0.020 |
Why?
|
| Hip Joint | 1 | 2013 | 406 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1989 | 34 | 0.020 |
Why?
|
| Osteoarthritis, Knee | 1 | 2013 | 400 | 0.020 |
Why?
|
| Pneumonia | 1 | 1989 | 75 | 0.020 |
Why?
|
| Knee Joint | 1 | 2013 | 826 | 0.020 |
Why?
|
| Coxiella burnetii | 1 | 2006 | 3 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2006 | 7 | 0.020 |
Why?
|
| Australia | 1 | 2006 | 45 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1133 | 0.020 |
Why?
|
| Drug Implants | 1 | 2005 | 11 | 0.020 |
Why?
|
| Osteomyelitis | 1 | 2005 | 23 | 0.020 |
Why?
|
| Dogs | 1 | 2005 | 263 | 0.020 |
Why?
|
| Radiography | 1 | 2005 | 695 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 56 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 246 | 0.010 |
Why?
|
| Macrolides | 1 | 1993 | 5 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1995 | 126 | 0.010 |
Why?
|
| Dysentery, Bacillary | 1 | 1990 | 2 | 0.010 |
Why?
|
| Campylobacter fetus | 1 | 1990 | 4 | 0.010 |
Why?
|
| Salmonella Infections | 1 | 1990 | 3 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1990 | 499 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1990 | 360 | 0.000 |
Why?
|